CLAIMS:

1. Use of sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$) in the manufacture of a medicament for reducing an inflammatory response due to a viral infection in a subject.

2. Use of sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$) in the manufacture of a medicament for treating or preventing an inflammatory condition due to a viral infection in a subject.

3. Use of sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$) in the manufacture of a medicament for treating or preventing hypercytokinemia due to a viral infection in a subject.

4. Use of sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$) in the manufacture of a medicament for treating a viral infection in a subject.

5. Use of sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$) in the manufacture of a medicament for reducing TNF-α, IL-1β, and/or IL-6 levels in a subject suffering from an inflammatory condition due to a viral infection.

6. The use of any one of claims 1 to 5, wherein the viral infection is a coronavirus infection.

7. The use of claim 6, wherein the coronavirus infection is caused by SARS-CoV-2.

8. Use of sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$) in the manufacture of a medicament for treating a coronavirus infection in a subject.

9. The use of claim 8, wherein the coronavirus infection is caused by SARS-CoV-2.

10. The use of any one of claims 1 to 9, wherein the medicament is formulated for oral administration.

11. The use of any one of claims 1 to 10, wherein the sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$) is to be administered at a dose in the range of from 2mg per day to 20 mg per day.

12. The use of any one of claims 1 to 11, wherein the medicament comprises a pharmaceutical composition comprising:

(a) a solid core comprising sodium meta-arsenite ($O=As-O^- Na^+$) or potassium meta-arsenite ($O=As-O^- K^+$), and one or more pharmaceutically acceptable

excipients, wherein the one or more pharmaceutically acceptable excipients are selected such that oxidation of meta-arsenite to meta-arsenate is minimised;

and

(b) an enteric coating comprising an enteric polymer;

wherein the weight percentage of the enteric coating is from about 6% w/w to about 20% w/w with respect to the total weight of the pharmaceutical composition, and wherein the coating thickness is from about 6.5% to about 15% of the thickness of the pharmaceutical composition.

13. The use of any one of claims 1 to 11, wherein the medicament comprises a pharmaceutical composition comprising:

(a) a solid core comprising sodium meta-arsenite ($O=As\text{-}O^{-}\ Na^{+}$) or potassium meta-arsenite ($O=As\text{-}O^{-}\ K^{+}$), and the following pharmaceutically acceptable excipients:

(i) a filler or diluent in a range of from about 5 to 95% w/w,

(ii) a disintegrant in a range of from about 10 to 90% w/w,

(iii) a glidant in a range of from about 0.1 to 5% w/w,

(iv) a lubricant in a range of from about 0.1 to 5% w/w, and

(v) optionally a binder in a range of from 0 to about 30% w/w;

and

(b) an enteric coating comprising an enteric polymer;

wherein the pharmaceutically acceptable excipients are selected such that oxidation of meta-arsenite to meta-arsenate is minimised,

wherein the weight percentage of the enteric coating is from about 6% w/w to about 20% w/w with respect to the total weight of the pharmaceutical composition, and

wherein the coating thickness is from about 6.5% to about 15% of the thickness of the pharmaceutical composition.